AR087363A1 - Uso del anticuerpo i-3859 para la deteccion y diagnostico de los canceres - Google Patents

Uso del anticuerpo i-3859 para la deteccion y diagnostico de los canceres

Info

Publication number
AR087363A1
AR087363A1 ARP120102745A ARP120102745A AR087363A1 AR 087363 A1 AR087363 A1 AR 087363A1 AR P120102745 A ARP120102745 A AR P120102745A AR P120102745 A ARP120102745 A AR P120102745A AR 087363 A1 AR087363 A1 AR 087363A1
Authority
AR
Argentina
Prior art keywords
diagnosis
antibody
canceres
detection
cxcr4
Prior art date
Application number
ARP120102745A
Other languages
English (en)
Original Assignee
Pf Medicament
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pf Medicament filed Critical Pf Medicament
Publication of AR087363A1 publication Critical patent/AR087363A1/es

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]

Abstract

La presente se refiere al uso de un anticuerpo anti-CXCR4 aislado en el diagnóstico de cáncer. En particular, se describen métodos para diagnosticar y/o pronosticar un trastorno oncogénico asociado con la expresión de CXCR4.
ARP120102745A 2011-07-29 2012-07-27 Uso del anticuerpo i-3859 para la deteccion y diagnostico de los canceres AR087363A1 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201161513345P 2011-07-29 2011-07-29
EP11306000 2011-07-29
PCT/EP2012/064876 WO2013017562A1 (en) 2011-07-29 2012-07-30 Use of the antibody i-3859 for the detection and diagnosis of cancer

Publications (1)

Publication Number Publication Date
AR087363A1 true AR087363A1 (es) 2014-03-19

Family

ID=47628653

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP120102745A AR087363A1 (es) 2011-07-29 2012-07-27 Uso del anticuerpo i-3859 para la deteccion y diagnostico de los canceres

Country Status (14)

Country Link
US (1) US20140170677A1 (es)
EP (1) EP2736926A1 (es)
JP (1) JP6138780B2 (es)
KR (1) KR20140047127A (es)
CN (1) CN103717620A (es)
AR (1) AR087363A1 (es)
AU (2) AU2012292116A1 (es)
BR (1) BR112014001979A2 (es)
CA (1) CA2842552A1 (es)
IL (1) IL230693A0 (es)
MX (1) MX2014001160A (es)
RU (1) RU2636032C2 (es)
WO (1) WO2013017562A1 (es)
ZA (1) ZA201400500B (es)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6232689B2 (ja) * 2015-06-25 2017-11-22 株式会社国際電気通信基礎技術研究所 多器官連関システムを基盤とした予測装置、及び予測プログラム
AU2016342355B2 (en) * 2015-10-23 2022-07-28 Novartis Ag Computer method and system for deriving cell-to-cell spatial proximities
WO2017106332A1 (en) 2015-12-14 2017-06-22 X4 Pharmaceuticals, Inc. Methods for treating cancer
CN114778845A (zh) 2016-03-29 2022-07-22 无限生物制药公司 药物组合物或食品组合物及评价活性成分体内效果的方法
US11337969B2 (en) 2016-04-08 2022-05-24 X4 Pharmaceuticals, Inc. Methods for treating cancer
WO2017220989A1 (en) 2016-06-20 2017-12-28 Kymab Limited Anti-pd-l1 and il-2 cytokines
JP2021502071A (ja) * 2017-11-07 2021-01-28 エックス４ ファーマシューティカルズ， インコーポレイテッド がんバイオマーカーおよびその使用方法
US20210025895A1 (en) * 2018-04-13 2021-01-28 X4 Pharmaceuticals, Inc. Cancer serum biomarkers and methods of use thereof

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1068357B2 (en) * 1998-03-30 2014-12-10 NorthWest Biotherapeutics, Inc. Therapeutic and diagnostic applications based on the role of the cxcr-4 gene in tumorigenesis
AU5811001A (en) 2000-05-09 2001-11-20 Univ British Columbia Cxcr4 antagonist treatment of hematopoietic cells
CA2412436C (en) 2000-06-05 2013-05-21 The Trustees Of Columbia University In The City Of New York Identification and use of human bone marrow-derived endothelial progenitor cells to improve myocardial function after ischemic injury
US20030199464A1 (en) 2002-04-23 2003-10-23 Silviu Itescu Regeneration of endogenous myocardial tissue by induction of neovascularization
US20050002939A1 (en) 2002-12-23 2005-01-06 Albert Zlotnik Tumor killing/tumor regression using CXCR4 antagonists
WO2004096839A1 (en) * 2003-05-02 2004-11-11 Polyphor Ag Template-fixed beta-hairpin peptidomimetics with cxcr4 antagonizing activity
US8329178B2 (en) * 2005-02-18 2012-12-11 Dana-Farber Cancer Institute, Inc. Antibodies against CXCR4 and methods of use thereof
EP1777523A1 (en) * 2005-10-19 2007-04-25 INSERM (Institut National de la Santé et de la Recherche Médicale) An in vitro method for the prognosis of progression of a cancer and of the outcome in a patient and means for performing said method
SI2066351T1 (sl) * 2006-10-02 2016-02-29 E.R. Squibb & Sons, L.L.C. Humana protitelesa, ki vežejo cxcr4 in njihova uporaba
EP2172485A1 (en) * 2008-10-01 2010-04-07 Pierre Fabre Medicament Novel anti CXCR4 antibodies and their use for the treatment of cancer
EP2246364A1 (en) * 2009-04-29 2010-11-03 Pierre Fabre Médicament Anti CXCR4 antibodies for the treatment of HIV

Also Published As

Publication number Publication date
ZA201400500B (en) 2014-11-26
US20140170677A1 (en) 2014-06-19
AU2012292116A1 (en) 2014-02-06
BR112014001979A2 (pt) 2017-02-21
AU2017204043A1 (en) 2017-07-06
CN103717620A (zh) 2014-04-09
RU2014103054A (ru) 2015-09-10
WO2013017562A1 (en) 2013-02-07
IL230693A0 (en) 2014-03-31
JP6138780B2 (ja) 2017-05-31
CA2842552A1 (en) 2013-02-07
EP2736926A1 (en) 2014-06-04
JP2014523920A (ja) 2014-09-18
KR20140047127A (ko) 2014-04-21
RU2636032C2 (ru) 2017-11-17
MX2014001160A (es) 2014-07-14

Similar Documents

Publication Publication Date Title
AR087363A1 (es) Uso del anticuerpo i-3859 para la deteccion y diagnostico de los canceres
CY1122676T1 (el) Αντισωματα εναντι της κλαυδινης 18.2 που ειναι χρησιμα στη διαγνωση του καρκινου
CL2016000883A1 (es) Compuestos macrocíclicos, inhibidores de antígeno prostático específico de membrana (psma); composición farmacéutica; complejo de metal; y su uso para preparar compuestos radiomarcados útiles para la formación de imágenes para diagnosticar y para el tratamiento de cáncer de próstata y/o metástasis de la misma.
CL2018000270A1 (es) Constructos de anticuerpo para cd70 y cd3.
GT201300276A (es) Uso del anticuerpo anti-cd19 inmunoconjugado con maitansinoide para el tratamiento del síntoma tumores de células b
EA201690617A1 (ru) Комбинирование anti-lag-3-антител и анти-pd-1-антител для лечения опухолей
EA201592269A1 (ru) Способы и композиции для снижения иммуносупрессии опухолевыми клетками
EA201491574A1 (ru) Применение car, основанных на icos, для усиления противоопухолевой активности и длительного сохранения car
UY33647A (es) ?agentes de unión a cd33?.
MX2015015561A (es) Biomarcadores relacionados a la funcion renal y metodos para usar los mismos.
BR112013010952A2 (pt) sistemas de rmn e métodos para a detecção rápida de analisados
PE20151921A1 (es) Virus de la enfermedad de newcastle y usos de los mismos
BR112014002140A2 (pt) anticorpo anti-cxcr4 e uso do mesmo para a detecção e o diagnóstico de câncer
BR112014012590A8 (pt) Anticorpos anti-cd98 e métodos de uso dos mesmos
BR112013005145A2 (pt) anticorpos anti-cxcl13 e métodos para seu uso
ECSP13013092A (es) Ensayo de lisiloxidasa-homólogo 2 y métodos de uso del mismo
TR201911039T4 (tr) Ptp1b ile ilişkili bir hastalığın tedavisine yönelik aminosteroidler.
MX2019006005A (es) Metodos para la deteccion de cancer.
MX2013011334A (es) Biomarcadores para pronosticar sensibilidad a tratamientos contra el cancer.
MX350807B (es) Composiciones y metodos para el analisis de cancer de prostata.
MX2016005854A (es) Anticuerpo anti-her3 alosterico de la neuregulina.
EA201691091A1 (ru) Диагностические реагенты для улучшенной in vivo или in vitro клеточно-опосредованной иммунологической диагностики туберкулеза
WO2011153485A3 (en) Use of the sparc microenvironment signature in the treatment of cancer
CO7051011A2 (es) Anticuerpos recombinantes con especificidad dual por gangliósidos y su uso
WO2013033459A3 (en) Compositions, methods and uses for peptides in diagnosis, progression and treatment of cancers

Legal Events

Date Code Title Description
FB Suspension of granting procedure